Disease Landscape and Forecast Insights

The treatment landscape for ovarian cancer has been revolutionized by the angiogenesis inhibitor bevacizumab and the PARP inhibitors olaparib (Lynparza; AstraZeneca / Merck & Co.), niraparib (…

CDK4/6 inhibitors (Pfizer’s palbociclib, Novartis’s ribociclib, and Eli Lilly’s abemaciclib) combined with endocrine therapy are central to the treatment of metastatic HR-positive / HER2-…

The hepatocellular carcinoma therapy market in China is poised to experience significant growth, driven by an aging population and the high prevalence of hepatitis B and C infection. Angiogenesis…

The introduction of the immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy, and Opdualag (Bristol Myers Squibb), as well as BRAF/MEK inhibitor combinations such as Roche /…

The treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC) continues to evolve with the expanding role of immune checkpoint inhibitors and novel targeted therapies. The…

China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…

Doublet or triplet chemotherapy alone or in combination with angiogenesis inhibitors remains the cornerstone of treatment for metastatic colorectal cancer. Patients without RAS mutations also…

The renal cell carcinoma therapy market is rapidly evolving and experiencing substantial growth, largely driven by the increasing uptake of immune checkpoint inhibitors. Combination regimens,…

The breast cancer therapy market in mainland China is one of the most dynamic in the oncology sector. Several new and emerging therapies are expected to gain approval for specific subpopulations,…

Immune checkpoint inhibitors Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) and Keytruda (Merck & Co.) have revolutionized the treatment of gastroesophageal cancer, driving substantial market…

Hormonal agents dominate the treatment landscape for prostate cancer and are routinely used in all lines of therapy. Second-generation hormone therapies have expanded beyond metastatic castrate-…

The multibillion-dollar NSCLC therapy market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck & Co.), which…